Ionis Pharmaceuticals (IONS) Net Cash Flow (2009 - 2026)

Ionis Pharmaceuticals' Net Cash Flow history runs 18 years deep, the most recent figure standing at -$198.7 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 1008.2% year-over-year to -$198.7 million in Q1 2026; TTM through Mar 2026 was -$91.1 million, a 7.52% decrease from a year earlier, with the FY2025 full-year figure at $129.5 million, up 182.52% from the prior year.
• Net Cash Flow eased to -$198.7 million in Q1 2026 per IONS's latest filing, from $34.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $115.7 million in Q2 2023 and bottomed at -$326.5 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$20.2 million (2022), against an average of -$40.9 million.
• Across the five-year window, Net Cash Flow sank 2065.0% in 2022 and jumped 673.14% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at -$39.1 million in 2022, then jumped by 219.99% to $46.9 million in 2023, then tumbled by 296.35% to -$92.0 million in 2024, then surged by 136.9% to $34.0 million in 2025, then slumped by 685.19% to -$198.7 million in 2026.
• Per Business Quant, the three latest IONS Net Cash Flow figures stand at -$198.7 million (Q1 2026), $34.0 million (Q4 2025), and $41.1 million (Q3 2025).